A/Prof Karen Sheppard
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
96 Scholarly works
8 Projects
HIGHLIGHTS
2025
Journal article
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
DOI: 10.1136/jitc-2025-0115512025
Journal article
BRAF/MEK inhibition following immune checkpoint inhibitors promotes antitumor immunity associated with expansion of progenitor-exhausted CD8⁺ T cells
DOI: 10.1016/j.ejcskn.2025.1007372024
Research grants (other domestic)
The Biology of Melanoma Organ-Specific Metastases and Response to Therapy
2019
Research Grant
Inhibition of Prmt5 as a Cancer Therapy
2017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
2014
Journal article
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
DOI: 10.1158/2159-8290.CD-13-04402013
Journal article
Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours
DOI: 10.1038/srep03494
RECENT SCHOLARLY WORKS
2024
Journal article
Intra- and inter-tumoral heterogeneity of melanoma across different metastatic sites
DOI: 10.1158/1538-7445.TUMBODY-B0012024
Journal article
Single cell RNA-sequencing coupled with lineage tracing identifies novel clonal populations associated with immunotherapy resistance
DOI: 10.1158/1538-7445.TUMBODY-C0442023
Journal article
PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma
DOI: 10.1371/journal.pone.02922782023
Journal article
Sequencing of targeted- and immune-therapy: delineating time dependent changes in both melanoma cells and the immune microenvironment
DOI: 10.1158/1538-7445.AM2023-59412023
Journal article
The therapeutic potential of targeting minimal residual disease in melanoma
DOI: 10.1002/ctm2.11972023
Journal article
Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
DOI: 10.1158/1535-7163.MCT-22-00922022
Journal article
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
DOI: 10.1038/s41698-022-00273-92022
Journal article
Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma
DOI: 10.1038/s41467-022-28705-x